216MO A randomized phase II trial of metronomic oral vinorelbine plus cyclophosphamide and capecitabine (VEX) vs weekly paclitaxel (P) as first- or second-line treatment in patients (pts) with ER+/HER2- metastatic breast cancer (MBC): The METEORA-II trial (IBCSG 54-16)

E Munzone,A Goldhirsch,M.A Colleoni,C Chini,F Puglisi,E Campadelli,C Bengala,C Zamagni,M.M Regan,S Cinieri,L Orlando,U.F.F De Giorgi,R Shi,E Montagna,D Generali,L Gianni,E Collova,E Cretella

doi:10.1016/j.annonc.2022.07.255

216MO A randomized phase II trial of metronomic oral vinorelbine plus cyclophosphamide and capecitabine (VEX) vs weekly paclitaxel (P) as first- or second-line treatment in patients (pts) with ER+/HER2- metastatic breast cancer (MBC): The METEORA-II trial (IBCSG 54-16)

E Munzone, A Goldhirsch + Show 16 more

Open Access

https://doi.org/10.1016/j.annonc.2022.07.255

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Sep 1, 2022
Citations: 1	License type: publisher-specific-oa

Affiliation: European Institute of Oncology, Istituti di Ricovero e Cura a Carattere Scientifico, University of Udine, Ospedale per gli Infermi, Ospedale Misericordia di Grosseto, Azienda USL di Bologna, Ospedale A. Perrino, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Dana-Farber Cancer Institute, University of Trieste, Ospedale Infermi di Rimini, Ospedale di Bolzano

#Metastatic Breast Cancer #To Treatment Failure + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

METEORA-II was designed to test the concept of the metronomic VEX regimen administered for as long as the pt has the possibility of deriving a benefit from it, in comparison with weekly P, for pts with ER+/HER2- MBC candidates for chemotherapy (CT). Time to treatment failure (TTF) was chosen as primary endpoint, as CT may be stopped due to lack of tolerability, lack of efficacy or pt preference.

Full Text